AstraZeneca stock price falls sharply on a $39 billion bill to buy Alexion

Investors don’t seem impressed with AstraZeneca’s (LON: AZN) latest deal, which is also the biggest deal in the company’s history.  Fundamental analysis: Hefty price paid The British-Swedish pharma giant agreed to pay $39 billion to buy Alexion Pharmaceuticals in a major push to increase its market share in the areas of immunology and rare-disease drugs. The deal is expected to be completed in Q3 2021.  Alexion shareholders will receive $60 in cash per share, in addition to $115 worth of equity per share to total $175 per share. This represents a premium of more than 40% compared to Friday’s closing